Arrowstreet Capital’s Acceleron Pharma XLRN Stock Holding History

Arrowstreet Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,018	Closed	-$1.13M	–	1997
2021 Q2	$1.13M	Buy	+9,018	New	+$1.14M	﹤0.01%	1503
2021 Q1	–	Sell	-126,533	Closed	-$16.2M	–	2663
2020 Q4	$16.2M	Buy	126,533 +23,721	+23%	+$2.78M	0.02%	671
2020 Q3	$11.6M	Buy	102,812 +78,512	+323%	+$7.82M	0.02%	772
2020 Q2	$2.31M	Buy	+24,300	New	+$2.34M	﹤0.01%	1417
2017 Q4	–	Sell	-12,000	Closed	-$448K	–	1436
2017 Q3	$448K	Buy	+12,000	New	+$417K	﹤0.01%	950
2016 Q4	–	Sell	-5,700	Closed	-$206K	–	2711
2016 Q3	$206K	Buy	+5,700	New	+$189K	﹤0.01%	1418

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital's XLRN Position: Q3 2021 in Review

Arrowstreet Capital sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 9,018 shares — an estimated $1.13M sold.

Arrowstreet Capital first reported a position in XLRN in Q3 2016 and held it in 6 quarters. The position peaked at $16.2M in Q4 2020. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Arrowstreet Capital reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
Arrowstreet Capital sold 9,018 Acceleron Pharma shares in Q3 2021, an estimated $1.13M.
Arrowstreet Capital first reported a position in Acceleron Pharma in Q3 2016 and held it in 6 quarters.
Arrowstreet Capital's Acceleron Pharma position peaked at $16.2M in Q4 2020.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Arrowstreet Capital's 13F filing for Q3 2021, filed 12 Nov 2021.